Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2025)

Bicycle Therapeutics' Cash from Financing Activities history spans 8 years, with the latest figure at -$15000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 107.39% year-over-year to -$15000.0; the TTM value through Dec 2025 reached -$131000.0, down 100.03%, while the annual FY2025 figure was -$131000.0, 100.03% down from the prior year.
  • Cash from Financing Activities reached -$15000.0 in Q4 2025 per BCYC's latest filing, up from -$30000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $549.6 million in Q2 2024 to a low of -$31.9 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $54.9 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: soared 3702850.0% in 2021, then tumbled 113.61% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $190.7 million in 2021, then crashed by 96.91% to $5.9 million in 2022, then plummeted by 93.44% to $386000.0 in 2023, then tumbled by 47.41% to $203000.0 in 2024, then plummeted by 107.39% to -$15000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Cash from Financing Activities are -$15000.0 (Q4 2025), -$30000.0 (Q3 2025), and -$45000.0 (Q2 2025).